Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol.
Calcimimetics decrease parathyroid hormone (PTH) levels in uremic patients with secondary hyperparathyroidism without increasing serum calcium (Ca). The aim of this study was to evaluate the effect of calcimimetic R-568 alone or in combination with calcitriol on vascular and other soft tissue calcifications in uremic rats with secondary hyperparathyroidism. Sham-operated and 5/6 nephrectomized Wistar rats were studied. 5/6 Nephrectomized rats were treated with vehicle, calcitriol (80 ng/kg every other day), R-568 (1.5 and 3 mg/kg per d), and both calcitriol and R-568 1.5 mg/kg, as above. Rats were killed after 14 or 56 d of treatment. Blood was drawn for biochemical measurements. Aortic, heart, kidney, lung, and stomach tissue samples were processed for histopathology and measurement of tissue Ca and phosphorus content. PTH concentrations were significantly reduced by all treatments. Treatment with calcitriol induced significant vascular calcification (aortic Ca increased to 4.2+/-1.2 mg/g at day 14 and to 11.4+/-0.7 mg/g at day 56; P<0.05 versus vehicle). Treatment with R-568 did not induce vascular calcification. Concurrent administration of R-568 with calcitriol reduced the aortic Ca (1.9+/-0.2 mg/g at day 14 and 7.5+/-1.4 mg/g at day 56) in relation to calcitriol alone. Soft tissue calcifications mirrored aortic mineralizations. Survival was significantly (P<0.001) reduced in calcitriol-treated rats, and mortality was attenuated (P=0.01) by concurrent treatment with R-568. In uremic rats, R-568 reduces elevated PTH levels without inducing vascular calcification, prevents calcitriol-induced vascular calcification, and decreases mortality.
Lopez
Ignacio
I
Department of Medicina y Cirugia Animal, Universidad de Cordoba, Campus Universitario Rabanales, Ctra. Madrid-Cadiz Km 396, 14014 Cordoba, Spain.
Aguilera-Tejero
Escolastico
E
Mendoza
Francisco J
FJ
Almaden
Yolanda
Y
Perez
Jose
J
Martin
David
D
Rodriguez
Mariano
M
D000814:Aniline Compounds / Q000494:pharmacology*; D000818:Animals; D001707:Biopsy, Needle; D001774:Blood Chemical Analysis; D002114:Calcinosis / Q000473:pathology* / Q000517:prevention & control*; D002117:Calcitriol / Q000494:pharmacology*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D007150:Immunohistochemistry; D008297:Male; D009392:Nephrectomy; D010627:Phenethylamines; D011336:Probability; D011437:Propylamines; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D012680:Sensitivity and Specificity; D015996:Survival Rate; D014511:Uremia / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology
D000814:Aniline Compounds; C107873:N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine; D010627:Phenethylamines; D011437:Propylamines; D012333:RNA, Messenger; D002117:Calcitriol